| Ytd | 15.75% | |
| 1y | -77.74% |
| Open | 5.02 | Prev Close | 2.97 | Low | 3.82 | High | 5.98 | Mkt Cap | 9.92M |
| Vol | 57.03M | Avg Vol | 1.84M | EPS | -10.75 | P/E | N/A | Forward P/E | -2.00 |
| Beta | 0.57 | Short Ratio | 1.96 | Inst. Own | 8.02% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-01 | 50-d Avg | 3.18 | 200-d Avg | 5.52 | 1yr Est | 14.00 |
CANF News
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Can Fite Biopharma (AMEX:CANF)
Gainers Can Fite Biopharma (AMEX:CANF) shares rose 43.8% to $4.27 during Wednesday's regular se
Can-Fite BioPharma Ltd. (NYSE:CANF) on Wednesday said its Phase 2a study of Namodenoson in advanced
Can-Fite's Phase 2a Namodenoson study met its safety endpoint and showed durable survival, suppo
Three emerging biotechnology companies, Can-Fite (NYSE: CANF), NeOnc (NASDAQ: NTHI), and PMGC (NASDA
Gainers Can Fite Biopharma (AMEX:CANF) stock moved upwards by 52.0% to $4.52 during Wednesday's
NKE: -9% | Nike shares are trading lower. The company reported Q4 financial results. BE: 12% | Bloom
Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced d
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday&
Can-Fite stock rises after Japan patent allowance strengthens Namodenoson’s obesity and metabolic di
Gainers Quantum Cyber (NASDAQ:QUCY) stock moved upwards by 63.4% to $2.37 during Friday's pre-m
ON: -14% | ON stock has given up its prior gain. ON Semiconductor shares were trading higher after t
The allowed Patent strengthens protection in one of the world's largest pharmaceutical markets a
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of pr
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of pr
D. Boral Capital analyst Jason Kolbert upgrades Can Fite Biopharma (AMEX:CANF) from Hold to Buy a
Phase 2b study design to be discussed at BIO International Convention in San Diego as Can-Fite advan
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Can Fite Biopharma (AMEX:CANF) w
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing
Vetbiolix, Can-Fite's veterinary commercialization partner, is funding all development costs ass
Strengthens global IP and supports strategic positioning in the rapidly growing metabolic therapeuti
U.S. stocks up on Wednesday with NASDAQ gaining 0.85%. ISM services PMI rose to 56.1. VCI Global Ltd
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF) ("Can-Fite" or the "Company"), a bi
Can-Fite stock jumps after Namodenoson improves survival in pancreatic cancer Phase 2a study with a
US stocks rise, with Dow up 0.25% and NASDAQ up 0.69%. Consumer discretionary shares increase by 1.1
MRNA: 11% | Moderna shares are trading higher after the company announced that it has entered into a
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing
Namodenoson's Favorable Safety Profile and Broad Patent Portfolio Positions it as a Promising Ca
Namodenoson's oral safety profile and metabolic activity, position it as a promising candidate i
Namodenoson Provided Clinical Stabilization as a Potential Bridge to Transplant in Advanced Liver Fa
U.S. stock futures slightly lower. UiPath joins S&P Midcap 400, Agios receives FDA approval, Can
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of pr
D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma (AMEX:CANF) with a Buy and low
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of pr